A comprehensive post-market review of studies on a probiotic product containing Lactobacillus helveticus R0052 and Lactobacillus rhamnosus R0011

Foster, Lauren M.; Tompkins, Thomas A.; Dahl, Wendy J.

doi:10.3920/bm2011.0032

Cited by 57 publications

(49 citation statements)

References 64 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The level of therapeutic efficacy of heat-treated and lyophilized L. acidophilus LB cells and culture medium against established infectious acute watery diarrhoea (MD −21.6 hours, 95% CI −26.5 to −16.6) [Szajewska et al 2014a] is close to the level found by Allen and colleagues [Allen et al 2010] in their Cochrane analysis of 63 RCTs L. rhamnosus R0011 (CNCM I-1720) and L. helveticus R0052 (CNCM I-1722) strains isolated from dairy [Foster et al 2011], there was only one RCT (unknown aetiology; MD −23.8 hours, 95% CI −60.0 to −9.6) [Szajewska et al 2014a].…”

Section: Comparison With Different Marketed Probiotic Lactobacillus Ssupporting

confidence: 62%

A gastrointestinal anti-infectious biotherapeutic agent: the heat-treated Lactobacillus LB

Moal

2015

Therap Adv Gastroenterol

View full text Add to dashboard Cite

Abstract:Experimental in vitro and in vivo studies support the hypothesis that heattreated, lyophilized Lactobacillus acidophilus LB cells and concentrated, neutralized spent culture medium conserve the variety of pharmacological, antimicrobial activities of the live probiotic strain against several infectious agents involved in well-established acute and persistent watery diarrhoea and gastritis. Heat-treated cells and heat-stable secreted molecules trigger multiple strain-specific activities explaining the therapeutic efficacy of L. acidophilus LB. This review discusses the current body of knowledge on the antimicrobial mechanisms of action exerted by L. acidophilus LB demonstrated in in vitro and in vivo experimental studies, and the evidence for the therapeutic efficacy of this anti-infectious biotherapeutic agent proved in randomized clinical trials for the treatment of acute and persistent watery diarrhoea associated with several intestinal infectious diseases in humans.

show abstract

Section: Comparison With Different Marketed Probiotic Lactobacillus Ssupporting

confidence: 62%

A gastrointestinal anti-infectious biotherapeutic agent: the heat-treated Lactobacillus LB

Moal

2015

Therap Adv Gastroenterol

View full text Add to dashboard Cite

show abstract

“…The probiotic strains were chosen for their commercial use in fermented food products such as cheese and yogurt, L. helveticus RO052 and L. rhamnosus RO011 originating from dairy products (Hagen et al, 2010; Foster et al, 2011). Both strains are resistant to acidic pH levels (Dimitrov et al, 2005; Succi et al, 2005) which are known to negatively affect probiotic viability, especially during dairy product storage (Champagne et al, 2005).…”

Section: Discussionmentioning

confidence: 99%

“…Toxicity studies for these two strains have been completed and no toxicity was observed (Foster et al, 2011). B. animalis subsp.…”

Section: Methodsmentioning

confidence: 99%

Assessment of Probiotic Viability during Cheddar Cheese Manufacture and Ripening Using Propidium Monoazide-PCR Quantification

Desfossés-Foucault¹,

Dussault-Lepage²,

Boucher³

et al. 2012

Front. Microbio.

View full text Add to dashboard Cite

The use of a suitable food carrier such as cheese could significantly enhance probiotic viability during storage. The main goal of this study was to assess viability of commercial probiotic strains during Cheddar cheesemaking and ripening (4–6 months) by comparing the efficiency of microbiological and molecular approaches. Molecular methods such as quantitative PCR (qPCR) allow bacterial quantification, and DNA-blocking molecules such as propidium monoazide (PMA) select only the living cells’ DNA. Cheese samples were manufactured with a lactococci starter and with one of three probiotic strains (Bifidobacterium animalis subsp. lactis BB-12, Lactobacillus rhamnosus RO011, or Lactobacillus helveticus RO052) or a mixed culture containing B. animalis subsp. lactis BB-12 and L. helveticus RO052 (MC1), both lactobacilli strains (MC2), or all three strains (MC3). DNA extractions were then carried out on PMA-treated and non-treated cell pellets in order to assess PMA treatment efficiency, followed by quantification using the 16S rRNA gene, the elongation factor Tu gene (tuf) or the transaldolase gene (tal). Results with intact/dead ratios of bacteria showed that PMA-treated cheese samples had a significantly lower bacterial count than non-treated DNA samples (P < 0.005), confirming that PMA did eliminate dead bacteria from PCR quantification. For both quantification methods, the addition of probiotic strains seemed to accelerate the loss of lactococci viability in comparison to control cheese samples, especially when L. helveticus RO052 was added. Viability of all three probiotic strains was also significantly reduced in mixed culture cheese samples (P < 0.0001), B. animalis subsp. lactis BB-12 being the most sensitive to the presence of other strains. However, all probiotic strains did retain their viability (log 9 cfu/g of cheese) throughout ripening. This study was successful in monitoring living probiotic species in Cheddar cheese samples through PMA-qPCR.

show abstract

“…The authors concluded that there is insufficient evidence to recommend L. acidophilus strain LB for treating diarrhea in children (24). Some studies also examined the effect of AGE treatment using other Lactobacillus species, some Bifidobacterium species, Streptococcus thermophilus, and other probiotics (25)(26)(27)(28). However, there is not enough evidence to recommend these probiotics for routine use in AGE (6).…”

Section: Placebo Groupmentioning

confidence: 99%

The role of Bifidobacterium lactis B94 plus inulin in the treatment of acute infectious diarrhea in children

İşlek

Sayar²,

Yılmaz³

et al. 2015

Turk J Gastroenterol

View full text Add to dashboard Cite

Background/Aims: In contrast to many other studies of probiotic species, the number of publications evaluating Bifidobacterium lactis and its combinations with prebiotics as treatments for acute infectious diarrhea is limited. We investigated the synbiotic effects of B. lactis B94 plus inulin on acute infectious diarrhea. Materials and Methods: The study was conducted on children with acute diarrhea between the ages of 2 and 60 months. The patients were administered 5×10 10 colony-forming units (CFU) of B. lactis B94 plus 900 mg inulin or placebo, once a day for five days. Stools were examined for Rotavirus, Adenovirus, Entamoeba histolytica, Salmonella, Shigella, Campylobacter, Clostridium difficile, Cryptosporidium, and parasites. Results: We examined 79 patients in the synbiotic group and 77 patients in the placebo group. The duration of diarrhea was significantly reduced in the synbiotic group in comparison with the placebo group (3.9±1.2 days vs. 5.2±1.3 days, respectively; p<0.001). Moreover, the number of diarrheal stools on the third day was significantly lower in the synbiotic group than in the placebo group (5.5±2.9 vs. 8.3±3.01, respectively; p<0.001). Diarrhea in the synbiotic-group patients with rotavirus infection was of a significantly shorter duration (3.2±1.3 days vs. 5.2±1.3 days, respectively; p=0.001). Duration of diarrhea in patients who started the synbiotic treatment within the first 24 h was shorter than that in the patients who started the treatment later (3.9±1.1 days vs. 4.8±1.8 days, respectively; p=0.002). Conclusion: Treatment with 5 × 10 10 CFU of B. lactis B94 plus 900 mg inulin shortened the duration of acute watery diarrhea by an average of 31 h. This decrease was most pronounced in cases of Rotavirus diarrhea.

show abstract

A comprehensive post-market review of studies on a probiotic product containing Lactobacillus helveticus R0052 and Lactobacillus rhamnosus R0011

Cited by 57 publications

References 64 publications

A gastrointestinal anti-infectious biotherapeutic agent: the heat-treated Lactobacillus LB

A gastrointestinal anti-infectious biotherapeutic agent: the heat-treated Lactobacillus LB

Assessment of Probiotic Viability during Cheddar Cheese Manufacture and Ripening Using Propidium Monoazide-PCR Quantification

The role of Bifidobacterium lactis B94 plus inulin in the treatment of acute infectious diarrhea in children

Contact Info

Product

Resources

About